Business Information
The group's principal activity is to develop and commercialize specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets. It also performs pharmaceutical research, targeting products and technologies related to specific diseases such as glaucoma, retinal disease, dry eye, psoriasis, acne and movement disorders. The group also develops and markets aesthetic-related pharmaceuticals and over-the-counter products. The group operates mainly in the United States, Europe, Latin America and Asia-Pacific.the group acquired bardeen sciences company, llc on 16-May-2003 and oculex pharmaceuticals, inc. On 20-Nov-2003.
|
|
Name |
Title
|
Email
|
| David Pyott | Chmn., CEO | Available | | Herbert Boyer | Vice Chmn. | N/A | | Michael Ball | Pres. | Available | | Douglas Ingram | Exec. VP, General Counsel, Sec. | Available | | James Barlow | Sr. VP, Corporate Controller | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 3,063,300 | (127,400) | | 2005 | 2,319,200 | 403,900 | | 2004 | 2,045,600 | 377,100
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
